Clinical Trials
Teneligliptin (Investigational) Add-On Therapy to Empagliflozin and Metformin in Type 2 Diabetes
Kwak et alJournal of diabetes investigation

In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, investigators evaluated the efficacy and safety of teneligliptin as add-on therapy in Korean patients with type 2 diabetes inadequately controlled on empagliflozin and metformin. Participants with baseline glycated hemoglobin (HbA1c) levels between 7.0% and 10.5% while receiving empagliflozin 10 mg plus metformin (≥1,000 mg/day) were randomly assigned to receive teneligliptin 20 mg once daily (n = 116) or placebo (n = 119) for 24 weeks. The primary endpoint was the change in HbA1c from baseline at week 24, while secondary endpoints assessed changes in fasting plasma glucose (FPG), the achievement rate of target HbA1c, and other metabolic parameters.
At week 24, the teneligliptin cohort showed a significant reduction in HbA1c compared with placebo, with a least-squares mean difference of -0.69% (95% CI, -0.83 to -0.54; P < 0.0001). Furthermore, the rate of achieving HbA1c < 7.0% was significantly higher in the teneligliptin group than in the placebo group (59.5% vs 21.9%; P < 0.0001). Significant reductions were also observed for FPG and glycated albumin in the teneligliptin arm relative to placebo. Teneligliptin was well tolerated, with no significant difference observed in the incidence of treatment-emergent adverse events between groups, suggesting it serves as a viable add-on option for patients who do not achieve adequate glycemic control on empagliflozin and metformin dual therapy.
Key Takeaways
- At week 24, adding teneligliptin 20 mg once daily resulted in a significant reduction in HbA1c compared with placebo (least-squares mean difference -0.69%; 95% CI, -0.83 to -0.54; P < 0.0001).
- A significantly higher proportion of patients achieved target HbA1c < 7.0% with teneligliptin compared to placebo (59.5% vs 21.9%; P < 0.0001).
- Teneligliptin produced significant reductions in fasting plasma glucose and glycated albumin versus placebo, with no significant difference in the incidence of treatment-emergent adverse events between groups.
Read the original sourceJournal of diabetes investigation
